Tectonic Therapeutic, Inc. — fact timeline

Tectonic Therapeutic, Inc. shareholders approved Advisory Approval on Executive Compensation at the 2026-06-08 meeting.

“Proposal 3: Advisory Approval on Executive Compensation The stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s Named Executive Officers, as disclosed in the Company’s proxy statement for the 2026 Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,292,497 118,271 14,467 2,806,066”

Tectonic Therapeutic, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2026-06-08 meeting.

“Proposal 2: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,225,948 3,831 1,522 0”

Tectonic Therapeutic, Inc. shareholders approved Election of Directors at the 2026-06-08 meeting.

“Proposal 1: Election of Directors Timothy A. Springer and Stefan Vitorovic were elected as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Timothy A. Springer 11,461,485 2,963,750 2,806,066 Stefan Vitorovic 13,937,996 487,239 2,806,066”

Tectonic Therapeutic, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update.”

Tectonic Therapeutic, Inc. underwent a change of control involving Tectonic Therapeutic, Inc. for 0.53441999 shares of the Company’s common stock for each share of Tectonic common stock (closed 2024-06-20).

“At the effective time of the Merger, the Company issued an aggregate of approximately 5,322,169 shares of its common stock to Tectonic stockholders, based on an exchange ratio of 0.53441999 (after giving effect to the Reverse Stock Split) shares of the Company’s common stock for each share of Tectonic common stock outstanding immediately prior to the Merger,”

Stefan Vitorovic was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Praveen Tipirneni was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Timothy A. Springer was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Terrance McGuire was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Alise Reicin was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Phillip B. Donenberg was appointed as Director at Tectonic Therapeutic, Inc..

“Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).”

Bruce Booth resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Annalisa Jenkins resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Ian Clark resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Philip J. Vickers resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Christopher Paige resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Gail Farfel resigned as Director at Tectonic Therapeutic, Inc..

“immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.”

Tectonic Therapeutic, Inc. entered into Agreement and Plan of Merger and Reorganization with AVROBIO, Inc. and Alpine Merger Subsidiary, Inc. (effective 2024-01-30).

“On January 30, 2024, AVROBIO, Inc., a Delaware corporation (“AVRO”), Alpine Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of AVRO (“Merger Sub”), and Tectonic Therapeutic, Inc., a Delaware corporation (“Tectonic”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”)”

Tectonic Therapeutic, Inc. announced a restructuring with charges of approximately $2.8 million (approximately 50%).

“Reduction will be offered separation benefits, including severance payments. The Company estimates that the severance and termination-related costs will total approximately $2.8 million in the aggregate and expects to primarily record these charges in the third quarter of 2023. The Company expects that payments of these costs will substantially be made through”

Tectonic Therapeutic, Inc. completed a disposition involving Novartis Pharma AG and Novartis Pharmaceuticals Corporation for $87.5 million (closed 2023-06-09).

“Hunter syndrome and Fabry disease, or indemnification claims under the Asset Purchase Agreement. The aggregate consideration to the Company consists of a cash payment of $87.5 million upon closing of the transaction on June 9, 2023 (the “Closing Date”). The Asset Purchase Agreement contains certain customary representations, warranties and covenants. The Asset”

Tectonic Therapeutic, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstentions Broker Non-Votes 34,092,579 33,201 677,016 --”

Tectonic Therapeutic, Inc. shareholders approved Election of two Class II directors at the 2023-06-06 meeting.

“The Company’s stockholders elected the two director nominees listed below to serve as Class II directors until the Company’s 2026 annual meeting of stockholders, with the votes cast as follows: Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 20,810,217 5,332,015 8,660,564 Annalisa Jenkins, M.B.B.S., F.R.C.P. 16,685,601 9,456,631 8,660,564”

Tectonic Therapeutic, Inc. announced a restructuring affecting cystinosis gene therapy program (designated AVR-RD-04).

“The Company is currently unable to make a determination of the estimated amount or range of amounts of the charge that will result in future cash expenditures in connection with the Asset Sale”

Tectonic Therapeutic, Inc. entered into Asset Purchase Agreement with Novartis Pharma AG and Novartis Pharmaceuticals Corporation valued at $87.5 million (effective 2023-05-19).

“On May 19, 2023, AVROBIO, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Novartis Pharma AG and Novartis Pharmaceuticals Corporation (collectively, the “ Purchaser ”), providing for the sale of the Company’s cystinosis gene therapy program”

Tectonic Therapeutic, Inc. reported the first quarter ended March 31, 2023 results: net income ($25.0 million).

“AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.”

Erik Ostrowski was appointed as President and Interim Chief Executive Officer at Tectonic Therapeutic, Inc..

“On April 28, 2023, the Board appointed Erik Ostrowski, the Company’s current Chief Financial Officer and Treasurer, as the Company’s President and Interim Chief Executive Officer, effective at 1:00 p.m. ET on May 1, 2023.”

Geoff MacKay resigned as President and Chief Executive Officer at Tectonic Therapeutic, Inc..

“On April 28, 2023, Geoff MacKay provided notice of his resignation as President and Chief Executive Officer and a member of the Board of Directors (the “ Board ”) of AVROBIO, Inc. (the “ Company ”), effective at 1:00 p.m. ET on May 1, 2023.”

Tectonic Therapeutic, Inc. reported financial results for the three months and year ended December 31, 2022.

“On March 23, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2022.”